PEPTIDES for Veterans Act and the Pentagon ban: what they say

In the United States, Rep. Nancy Mace (R-S.C.) is pushing two measures that would bring peptides into the military sphere: a bill directing the Department of Veterans Affairs (VA) to study peptide-based therapies, and an amendment to the annual defense bill (NDAA) that would limit the Pentagon's ability to ban them as supplement ingredients¹²³. This article separates what each text orders from what supporters and critics say it will do. It is regulatory and evidence reporting for physicians, not a recommendation for use.

What the VA bill, H.R. 10212, orders

The "Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act," known as the PEPTIDES for Veterans Act, was introduced by Mace on September 1, 2026 and referred to the House Committee on Veterans' Affairs; on September 8 it went to the Subcommittee on Health⁵⁶. No cosponsors or other legislative actions are listed⁶. The secondary sources that summarize the text caution that their summaries may contain mistakes; the official text is on Congress.gov, which was not reachable from our system⁵.

According to those summaries, the VA must review federal rules and guidance on peptides and set a definition of "peptide" and "peptide-based therapy," then report to Congress within 180 days of enactment (Stars and Stripes describes this as six months)³⁵⁷. A study of safety and efficacy in VA patients would follow, covering recovery, chronic pain and mental health; Stars and Stripes describes it as an 18-month study³⁵⁷.

The key point is the sequence: a voluntary pilot for veterans of up to five years would be authorized only if the VA concludes the therapies should be offered, and Stars and Stripes specifies it would depend on the study's initial findings being positive³⁵. In other words, the bill does not create access to any peptide by itself: it orders definition, reporting and study.

The NDAA amendment and the prohibited-supplement list

The second measure is more direct. In her office's June 8, 2026 release on the FY2027 NDAA markup, Mace lists amendment 6091: "legally available peptides may not be included on the prohibited dietary supplement ingredients list"⁴. The release says the NDAA "will now head to the House floor"; we could not confirm the date of a later vote on a page we opened⁴.

Reports from WUNC and WHRO (American Homefront Project, October 29 and November 2, 2026) describe the language as part of the House version and say the final wording must still be negotiated with the Senate¹². No rule is in force.

What the Pentagon says about peptides today

Operation Supplement Safety (OPSS), the Defense Department's supplement-education program, states that peptide hormones are on the prohibited-ingredient list and prohibited for service members⁹. Its BPC-157 page says the compound is on that list, is "an unapproved drug and cannot be legally prescribed or sold over the counter," and advises avoiding "research chemicals" (posted April 29, 2025)⁸. The U.S. Anti-Doping Agency adds that BPC-157 is prohibited by WADA under category S0, non-approved substances, and that there are no human clinical trials establishing efficacy for any diagnosis or treatment¹⁰.

The clinical evidence behind the debate

A 2025 systematic review in HSS Journal on BPC-157 in orthopaedic sports medicine identified 544 articles and included 36 studies after screening: 35 preclinical and 1 clinical, a retrospective study of intra-articular injection for chronic knee pain in which 7 of 12 patients reported relief for more than six months¹¹. Small human pilots have also been published in Alternative Therapies in Health and Medicine, such as a 2025 safety pilot of intravenous infusion¹². None is a randomized controlled trial. That gap is what the VA bill says it wants to close.

Meanwhile the VA is already running a trial of an approved peptide: the CRAVE study, announced July 30, 2026, randomizes more than 600 veterans with moderate or severe alcohol use disorder at 18 medical centers to weekly semaglutide or placebo for 24 weeks; the VA itself says larger controlled trials are needed and warns veterans not to self-medicate¹³. That is the study-first model the bill's supporters point to.

The objections: vulnerable populations and the supply chain

Shabbir Imber Safdar, executive director of the Partnership for Safe Medicines, told WUNC and WHRO that service members are "a particularly vulnerable patient community for performance enhancing drugs that are unsafe and unproved," that the ingredients come primarily from Chinese manufacturers, and that "there's definitely sterility risks with how they're being made now"¹². According to those reports, the American Medical Association and other groups are wary of legalizing peptides that have not gone through FDA approval testing¹². The same reports note that the FDA advisory committee that endorsed adding about six peptides to the compounding list did so despite advice against from agency scientists, and that the Associated Press reported ties between several members and clinics and telehealth companies¹².

How the HHS interim policy fits in

On October 28, 2026, HHS announced a draft enforcement-discretion policy for six peptides (BPC-157, epitalon, KPV, MOTS-c, semax and TB-500), published in the Federal Register on October 30 with comments due November 13¹⁴¹⁵. The law firms analyzing it stress that it "does not approve any peptide," does not add them to the 503A bulks list, does not bind the states and can be withdrawn; Venable summarizes it as "enforcement discretion is not legalization"¹⁴¹⁵. None of the sources we reviewed addresses whether a peptide compounded under that policy would count as "legally available" for purposes of Mace's amendment; that is an open question of interpretation, not an established fact.

What to watch

• Whether H.R. 10212 gets a hearing or cosponsors in the Veterans' Affairs Committee; today it has none⁶.
• The final wording of the amendment in the House–Senate NDAA reconciliation¹².
• Whether HHS's interim policy is finalized and how the Defense Department reads it¹⁴¹⁵.
• Results of controlled trials such as CRAVE, which show what the evidence looks like when a peptide is actually put through a study¹³.